Pennsylvania | 33-0272839 | |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
Large accelerated filer | o | Accelerated filer | o | |||
Non-accelerated filer | o (Do not check if a smaller reporting company) | Smaller reporting company | x | |||
Emerging growth company | o |
TABLE OF CONTENTS | ||
Page | ||
Item I. | ||
Condensed Consolidated Balance Sheets as of September 30, 2018 and June 30, 2018 (Unaudited) | ||
Item 2. | ||
Item 3. | ||
Item 4. | ||
Item 6. |
ESCALON MEDICAL CORP. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE (UNAUDITED) | |||||||
September 30, 2018 | June 30, 2018 | ||||||
ASSETS | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 914,616 | $ | 874,002 | |||
Restricted cash | 250,781 | 250,000 | |||||
Accounts receivable, net | 1,422,476 | 1,387,133 | |||||
Inventories, net | 1,765,182 | 1,823,414 | |||||
Other current assets | 257,047 | 249,620 | |||||
Total current assets | 4,610,102 | 4,584,169 | |||||
Property and equipment, net | 74,501 | 76,268 | |||||
Trademarks and trade names | 605,006 | 605,006 | |||||
License, net | 156,437 | 161,350 | |||||
Total assets | $ | 5,446,046 | $ | 5,426,793 | |||
LIABILITIES AND SHAREHOLDERS’ EQUITY | |||||||
Current liabilities: | |||||||
Line of credit | $ | 201,575 | $ | 165,000 | |||
Current portion of note payable | 3,491 | 3,153 | |||||
Accounts payable | 678,997 | 528,844 | |||||
Accrued expenses | 744,164 | 874,421 | |||||
Current portion of post-retirement benefits (related party) | 101,891 | 101,891 | |||||
Deferred revenue | 498,286 | 481,180 | |||||
Liabilities of discontinued operations | 92,810 | 92,532 | |||||
Total current liabilities | 2,321,214 | 2,247,021 | |||||
Note payable, net of current portion | 17,193 | 18,037 | |||||
Accrued post-retirement benefits, net of current portion (related party) | 743,120 | 749,480 | |||||
Total long-term liabilities | 760,313 | 767,517 | |||||
Total liabilities | 3,081,527 | 3,014,538 | |||||
Commitments and contingencies | |||||||
Shareholders' equity: | |||||||
Series A convertible preferred stock, $0.001 par value; 2,000,000 shares authorized; 2,000,000 shares issued and outstanding at September 30, 2018 and at June 30, 2018 (liquidation value of $677,373 and $664,368 as of September 30, 2018 and June 30, 2018) | 645,000 | 645,000 | |||||
Common stock, $0.001 par value; 35,000,000 shares authorized; 7,415,329 shares issued and outstanding as of September 30, 2018 and June 30, 2018 | 7,415 | 7,415 | |||||
Additional paid-in capital | 69,702,043 | 69,702,043 | |||||
Accumulated deficit | (67,989,939 | ) | (67,942,203 | ) | |||
Total shareholders’ equity | 2,364,519 | 2,412,255 | |||||
Total liabilities and shareholders’ equity | $ | 5,446,046 | $ | 5,426,793 |
ESCALON MEDICAL CORP. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) | |||||||
For the Three Months Ended September 30, | |||||||
2018 | 2017 | ||||||
Net revenues: | |||||||
Products | $ | 2,022,383 | $ | 2,426,624 | |||
Service plans | 236,000 | 203,000 | |||||
Revenues, net | 2,258,383 | 2,629,624 | |||||
Costs and expenses: | |||||||
Cost of goods sold | 1,203,133 | 1,467,310 | |||||
Marketing, general and administrative | 1,002,237 | 996,505 | |||||
Research and development | 96,408 | 193,081 | |||||
Total costs and expenses | 2,301,778 | 2,656,896 | |||||
Loss from operations | (43,395 | ) | (27,272 | ) | |||
Other income (expense) | |||||||
Interest income | 2,510 | 199 | |||||
Interest expense | (6,851 | ) | (33,448 | ) | |||
Total other income (expense) | (4,341 | ) | (33,249 | ) | |||
Net loss | $ | (47,736 | ) | $ | (60,521 | ) | |
Undeclared dividends on preferred stock | 13,005 | — | |||||
Net loss applicable to common shareholders | $ | (60,741 | ) | $ | (60,521 | ) | |
Net loss per share | |||||||
Basic loss per share | $ | (0.01 | ) | $ | (0.01 | ) | |
Diluted loss per share | $ | (0.01 | ) | $ | (0.01 | ) | |
Weighted average shares—basic | 7,415,329 | 7,551,430 | |||||
Weighted average shares—diluted | 7,415,329 | 7,551,430 |
ESCALON MEDICAL CORP. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY FOR THE THEE MONTHS ENDED SEPTEMBER 30, 2018 (UNAUDITED) | |||||||||||||||||||||||||
Common Stock | Series A Convertible Preferred Stock | Additional Paid-in Capital | Accumulated Deficit | Total Shareholders’ Equity | |||||||||||||||||||||
Shares | Amount | Shares | Amount | ||||||||||||||||||||||
Balance at June 30, 2018 | 7,415,329 | $ | 7,415 | 2,000,000 | $ | 645,000 | $ | 69,702,043 | $ | (67,942,203 | ) | $ | 2,412,255 | ||||||||||||
Net loss | — | — | — | — | — | (47,736 | ) | (47,736 | ) | ||||||||||||||||
Balance at September 30, 2018 | 7,415,329 | $ | 7,415 | 2,000,000 | $ | 645,000 | $ | 69,702,043 | $ | (67,989,939 | ) | $ | 2,364,519 |
ESCALON MEDICAL CORP. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) | |||||||
For the Three Months Ended September 30, | |||||||
2018 | 2017 | ||||||
Cash Flows from Operating Activities: | |||||||
Net loss | $ | (47,736 | ) | $ | (60,521 | ) | |
Adjustments to reconcile net loss to cash provided by (used in) operating activities: | |||||||
Depreciation and amortization | 13,186 | 11,855 | |||||
Change in operating assets and liabilities: | |||||||
Accounts receivable | (35,343 | ) | (45,532 | ) | |||
Inventories | 58,232 | (100,948 | ) | ||||
Other current assets | (7,427 | ) | (20,922 | ) | |||
Accounts payable and accrued expenses | 19,896 | (3,061 | ) | ||||
Accrued post-retirement benefits | (6,360 | ) | (18,490 | ) | |||
Deferred revenue | 17,106 | 59,811 | |||||
Liabilities of discontinued operations | 278 | 3,281 | |||||
Net cash provided by (used in) operating activities | 11,832 | (174,527 | ) | ||||
Cash Flows from Investing Activities: | |||||||
Purchase of equipment | (6,506 | ) | (2,206 | ) | |||
Purchase of licenses | — | (12,500 | ) | ||||
Net cash used in investing activities | (6,506 | ) | (14,706 | ) | |||
Cash Flows from Financing Activities: | |||||||
Proceeds from related party note payable | — | 100,000 | |||||
Repayment of note payable | (506 | ) | — | ||||
Proceeds from (repayment of ) line of credit | 36,575 | (25,000 | ) | ||||
Net cash provided by financing activities | 36,069 | 75,000 | |||||
Net increase (decrease) in cash, cash equivalents and restricted cash | 41,395 | (114,233 | ) | ||||
Cash, cash equivalents and restricted cash, beginning of period | 1,124,002 | 544,118 | |||||
Cash, cash equivalents and restricted cash, end of period | $ | 1,165,397 | $ | 429,885 | |||
Cash, cash equivalents and restricted cash consist of the following: | |||||||
End of period | |||||||
Cash and cash equivalents | $ | 914,616 | $ | 429,885 | |||
Restricted cash | $ | 250,781 | $ | — | |||
$ | 1,165,397 | $ | 429,885 | ||||
Beginning of period | |||||||
Cash and cash equivalents | $ | 874,002 | $ | 544,118 | |||
Restricted cash | $ | 250,000 | $ | — | |||
$ | 1,124,002 | $ | 544,118 | ||||
Supplemental Schedule of Cash Flow Information: | |||||||
Interest paid | $ | 35,648 | $ | 10,587 |
For the Three-months Ended September 30, | ||||||||
2018 | 2017 | |||||||
Numerator: | ||||||||
Numerator for basic earnings per share | ||||||||
Net loss | $ | (47,736 | ) | $ | (60,521 | ) | ||
Undeclared dividends on preferred stock | 13,005 | — | ||||||
Net loss applicable to common shareholders | $ | (60,741 | ) | $ | (60,521 | ) | ||
Numerator for diluted earnings per share: | ||||||||
Net loss applicable to common shareholders | $ | (60,741 | ) | $ | (60,521 | ) | ||
Undeclared dividends on preferred stock | 13,005 | — | ||||||
Net loss | $ | (47,736 | ) | $ | (60,521 | ) | ||
Denominator: | ||||||||
Denominator for basic earnings per share - weighted average shares outstanding | 7,415,329 | 7,551,430 | ||||||
Effect of dilutive securities: stock options | — | — | ||||||
Weighted average preferred stock converted to common stock | — | — | ||||||
Denominator for diluted earnings per share - weighted average and assumed conversion | 7,415,329 | 7,551,430 | ||||||
Net loss per share | ||||||||
Basic net loss per share | $ | (0.01 | ) | $ | (0.01 | ) | ||
Diluted net loss per share | $ | (0.01 | ) | $ | (0.01 | ) |
September 30, | |||
2018 | 2017 | ||
Convertible preferred stock | 4,300,000 | — | |
Stock options | 213,000 | 502,000 | |
Total potential dilutive securities not included in income per share | 4,513,000 | 502,000 |
(In thousands) | September 30, | June 30, | |||||
2018 | 2018 | ||||||
Inventories, net: | |||||||
Raw Material | $ | 616 | $ | 653 | |||
Work-In-Process | 237 | 192 | |||||
Finished Goods | 912 | 978 | |||||
Total | $ | 1,765 | $ | 1,823 |
September 30, | June 30, | ||||||
2018 | 2018 | ||||||
Assets | |||||||
Total assets | $ | — | $ | — | |||
Liabilities | |||||||
Accrued lease termination costs | 93 | 93 | |||||
Total liabilities | 93 | 93 | |||||
Net liabilities of discontinued operations | $ | (93 | ) | $ | (93 | ) |
Year Ending June 30, | Lease Obligations | ||
Remaining of fiscal year 2019 | $ | 273,275 | |
2020 | 268,469 | ||
2021 | 182,972 | ||
2022 | 178,535 | ||
2023 | 183,892 | ||
Thereafter | 286,239 | ||
Total | $ | 1,373,382 |
Three-month Periods Ended September 30, | |||||||||||
2018 | 2017 | ||||||||||
1,469,000 | 65.06 | % | 1,747,000 | 66.43 | % | ||||||
789,000 | 34.94 | % | 883,000 | 33.57 | % | ||||||
2,258,000 | 100.00 | % | 2,630,000 | 100.00 | % |
• | Unsatisfied Performance Obligations - all performance obligations relate to contracts with a duration of less than one year, the Company has elected to apply the optional exemption provided in ASC 606 and therefore, is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. |
• | Contract Costs - all incremental customer contract acquisition costs are expensed as they are incurred as the amortization period of the asset that the Company otherwise would have recognized is one year or less in duration. |
• | Significant Financing Component - the Company does not adjust the promised amount of consideration for the effects of a significant financing component as the Company expects, at contract inception, that the period between when the entity transfers a promised good or service to a customer and when the customer pays for that |
• | Sales Tax Exclusion from the Transaction Price - the Company excludes from the measurement of the transaction price all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the Company from the customer. |
• | Shipping and Handling Activities - the Company elected to account for shipping and handling activities as a fulfillment cost rather than as a separate performance obligation. |
• | Modified Retrospective Method - the Company adopted ASC 606 on July 1, 2018 utilizing the modified retrospective method allowing the Company to not retrospectively adjust prior periods. The Company applied the modified retrospective method only to contracts that were not completed at July 1, 2018 and accounted for the aggregate effect of any contract modifications upon adoption. |
• | Portfolio Approach - the Company applied the Portfolio Approach to contract reviews within its identified revenue streams that have similar characteristics and the Company believes this approach would not differ materially than if applying Topic 606 to each individual contract |
• | Total net revenue from continuing operations decreased approximately $372,000 or 14.1% during the thee-month period ended September 30, 2018 as compared to the prior fiscal year. The decrease in net revenue is attributed to a decrease in Escalon Digital Solutions, Inc. (EMI) total product sales of $169,000, related to a decrease in ophthalmic fundus photography system product sales, a decrease in sales of Trek products of $39,000 and a decrease in sales in Sonomed's ultrasound products of $164,000. |
• | Cost of goods sold as a percentage of total revenue decreased to approximately 53.3% of product revenues during the thee-month period ended September 30, 2018, as compared to approximately 55.8% of total revenue for the prior fiscal year. The decrease of 2.5% in cost of goods sold as a percentage of total revenue is mainly due to changes in product sales mix, including a decrease in ophthalmic fundus photography system product sales, which historically had a lower margin. |
• | Marketing general and administrative expenses and research and development expenses decreased approximately 7.7% during the thee-month period ended September 30, 2018, as compared to the prior fiscal year. This was due to decrease of 50.3% in research and development expenses, primarily due to cost savings initiatives, which was offset by an increased marketing, general and administrative expenses of 0.5%. |
Three-month Periods Ended September 30, | ||||||||||
2018 | 2017 | % Change | ||||||||
Net Revenue: | ||||||||||
Products | $ | 2,022 | $ | 2,427 | (16.7 | )% | ||||
Service plans | $ | 236 | $ | 203 | 16.3 | % | ||||
Total | $ | 2,258 | $ | 2,630 | (14.1 | )% |
Three-month Periods Ended September 30, | |||||||||||||
2018 | % | 2017 | % | ||||||||||
Cost of Goods Sold: | |||||||||||||
$ | 1,203 | 53.3 | % | $ | 1,467 | 55.8 | % | ||||||
Total | $ | 1,203 | 53.3 | % | $ | 1,467 | 55.8 | % |
Three-month Periods Ended September 30, | ||||||||||
2018 | 2017 | % Change | ||||||||
Marketing, General and Administrative: | ||||||||||
$ | 1,002 | $ | 997 | 0.5 | % | |||||
Total | $ | 1,002 | $ | 997 | 0.5 | % |
Three-month Periods Ended September 30, | ||||||||||
2018 | 2017 | % Change | ||||||||
Research and Development: | ||||||||||
$ | 96 | $ | 193 | (50.3 | )% | |||||
Total | $ | 96 | $ | 193 | (50.3 | )% |
September 30, | June 30, | ||||||
2018 | 2018 | ||||||
Current Ratio: | |||||||
Current assets | $ | 4,610 | $ | 4,584 | |||
Less: Current liabilities | 2,321 | 2,247 | |||||
Working capital | $ | 2,289 | $ | 2,337 | |||
Current ratio | 1.99 to 1 | 2.04 to 1 | |||||
Debt to Total Capital Ratio: | |||||||
Line of credit and note payable | $ | 222 | $ | 186 | |||
Total debt | 222 | 186 | |||||
Total equity | 2,365 | 2,412 | |||||
Total capital | $ | 2,587 | $ | 2,598 | |||
Total debt to total capital | 8.6 | % | 7.0 | % |
3-5 | More than | |||||||||||||||||||
Total | 1 Year | 2-3 Years | Years | 5 Years | ||||||||||||||||
Operating lease agreements | $ | 1,373,382 | $ | 349,986 | $ | 418,383 | $ | 365,085 | $ | 239,928 | ||||||||||
Total | $ | 1,373,382 | $ | 349,986 | $ | 418,383 | $ | 365,085 | $ | 239,928 |
Escalon Medical Corp. | ||||
(Registrant) | ||||
Date: November 14, 2018 | By: | /s/ Richard J. DePiano, Jr. | ||
Richard J. DePiano, Jr. | ||||
Chief Executive Officer | ||||
Date: November 14, 2018 | By: | /s/ Mark Wallace | ||
Mark Wallace | ||||
Chief Operating Officer and Principal Accounting & Financial Officer |
1. | I have reviewed this quarterly report on Form 10Q of Escalon Medical Corp.; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a. | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b. | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c. | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d. | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
a. | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
b. | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
/s/ Richard J. DePiano Jr. | |
Richard J. DePiano Jr. | |
Chief Executive Officer | |
Date: November 14, 2018 |
1. | I have reviewed this quarterly report on Form 10Q of Escalon Medical Corp.; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a. | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b. | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c. | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d. | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
a. | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
b. | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
/s/ Mark Wallace | |
Mark Wallace | |
Chief Operating Officer and Principal Accounting & Financial Officer | |
Date: November 14, 2018 |
1. | The Quarterly Report of Escalon Medical Corp. on Form 10Q for the quarterly period ended September 30, 2018 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
/s/ Richard J. DePiano Jr. | |
Richard J. DePiano Jr. | |
Chief Executive Officer |
1. | The Quarterly Report of Escalon Medical Corp. on Form 10-Q for the quarterly period ended September 30, 2018 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
/s/ Mark Wallace | |
Mark Wallace | |
Chief Operating Officer and Principal Accounting & Financial Officer |
Document And Entity Information - USD ($) |
3 Months Ended | |
---|---|---|
Sep. 30, 2018 |
Dec. 31, 2017 |
|
Document And Entity Information [Abstract] | ||
Entity Registrant Name | ESCALON MEDICAL CORP. | |
Entity Central Index Key | 0000862668 | |
Current Fiscal Year End Date | --06-30 | |
Entity Filer Category | Smaller Reporting Company | |
Document Type | 10-Q | |
Document Period End Date | Sep. 30, 2018 | |
Document Fiscal Year Focus | 2019 | |
Document Fiscal Period Focus | Q1 | |
Amendment Flag | false | |
Entity Common Stock, Shares Outstanding | 7,415,329 | |
Entity Public Float | $ 1,585,000 |
Consolidated Balance Sheets (Parenthetical) - $ / shares |
Sep. 30, 2018 |
Jun. 30, 2018 |
---|---|---|
Statement of Financial Position [Abstract] | ||
Preferred stock, par value | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized | 2,000,000 | 2,000,000 |
Preferred Stock, Shares Issued | 2,000,000 | 2,000,000 |
Common stock, par value | $ 0.001 | $ 0.001 |
Common stock, shares authorized | 35,000,000 | 35,000,000 |
Common stock, shares issued | 7,415,329 | 7,415,329 |
Common stock, shares outstanding | 7,415,329 | 7,415,329 |
Consolidated Statements Of Operations - USD ($) |
3 Months Ended | |
---|---|---|
Sep. 30, 2018 |
Sep. 30, 2017 |
|
Net revenues: | ||
Product revenue | $ 2,022,383 | $ 2,426,624 |
Sales Revenue, Services, Net | 236,000 | 203,000 |
Revenues, net | 2,258,383 | 2,629,624 |
Costs and expenses: | ||
Cost of Goods and Services Sold | 1,203,133 | 1,467,310 |
Marketing, general and administrative | 1,002,237 | 996,505 |
Research and development | 96,408 | 193,081 |
Total costs and expenses | 2,301,778 | 2,656,896 |
Loss from operations | (43,395) | (27,272) |
Other (expense) income: | ||
Interest income | 2,510 | 199 |
Interest expense | 6,851 | 33,448 |
Total other (expense) income | (4,341) | (33,249) |
Net loss | (47,736) | (60,521) |
Preferred Stock Dividends and Other Adjustments | 13,005 | 0 |
Net Income (Loss) Available to Common Stockholders, Basic | $ (60,741) | $ (60,521) |
Net income (loss) per share | ||
Basic earning per share | $ (0.01) | $ (0.01) |
Diluted earning per share | $ (0.01) | $ (0.01) |
Weighted average shares - basic | 7,415,329 | 7,551,430 |
Weighted average shares - diluted | 7,415,329 | 7,551,430 |
Consolidated Statements Of Shareholders' Equity and Comprehensive Loss - USD ($) |
Total |
Preferred Stock [Member] |
Common Stock [Member] |
Additional Paid-in Capital [Member] |
Accumulated Deficit [Member] |
---|---|---|---|---|---|
Preferred Stock, Shares Outstanding | 2,000,000 | ||||
Preferred Stock, Shares Issued | 2,000,000 | ||||
Preferred Stock, Value, Issued | $ 645,000 | ||||
Preferred Stock, Value, Outstanding | $ 645,000 | ||||
Balance at Jun. 30, 2018 | 2,412,255 | $ 7,415 | $ 69,702,043 | $ (67,942,203) | |
Balance, shares at Jun. 30, 2018 | 7,415,329 | ||||
Net loss | (47,736) | $ 0 | $ 0 | 0 | (47,736) |
Balance at Sep. 30, 2018 | $ 2,364,519 | $ 7,415 | $ 69,702,043 | $ (67,989,939) | |
Balance, shares at Sep. 30, 2018 | 7,415,329 | ||||
Preferred Stock, Shares Outstanding | 2,000,000 | ||||
Preferred Stock, Shares Issued | 2,000,000 | ||||
Preferred Stock, Value, Issued | $ 645,000 | ||||
Preferred Stock, Value, Outstanding | $ 645,000 |
Organization and Description of Business |
3 Months Ended |
---|---|
Sep. 30, 2018 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Organization and Description of Business and Business Conditions | Escalon Medical Corp. ("Escalon" or "Company") is a Pennsylvania corporation initially incorporated in California in 1987, and reincorporated in Pennsylvania in November 2001. Within this document, the “Company” collectively shall mean Escalon, which includes its division called "Trek" and its wholly owned subsidiaries: Sonomed, Inc. (“Sonomed”), Escalon Digital Solutions, Inc. (“EMI”), Escalon Holdings, Inc. (“EHI”), Escalon IP Holdings, Inc., and Sonomed IP Holdings, Inc.. All intercompany accounts and transactions have been eliminated. The Company operates in the healthcare market, specializing in the development, manufacture, marketing and distribution of medical devices and pharmaceuticals in the area of ophthalmology. The Company and its products are subject to regulation and inspection by the United States Food and Drug Administration (the “FDA”). The FDA and other government authorities requires extensive testing of new products prior to sale and has jurisdiction over the safety, efficacy and manufacture of products, as well as product labeling and marketing. The unaudited condensed consolidated financial statements included herein have been prepared pursuant to the rules and regulations of the Security and Exchange Commission, and reflect all adjustments (consisting of only normal and recurring adjustments) which are, in the opinion of management, necessary to present fairly the unaudited condensed consolidated financial information required herein. Certain information and note disclosures normally included in financial statement prepared in accordance with accounting principles generally accepted in the United Statements of America ("US GAAP") have been condensed or omitted pursuant to such rules and regulations. While management believes that the disclosures are adequate to make the information presented not misleading, it is suggested that these unaudited condensed consolidated financial statements be read in conjunction with the consolidated financial statements and the notes thereto included in the Company's Annual Report on Form 10-K filed with the Security and Exchange Commission for the fiscal year ended June 30, 2018. The Company’s common stock trades on the OTCQB Market under the symbol “ESMC.” |
Going concern (Notes) |
3 Months Ended |
---|---|
Sep. 30, 2018 | |
Going concern [Abstract] | |
Liquidity Disclosure [Policy Text Block] | . Going Concern The Company’s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to: the continuous enhancement of the current products, development of new products; changes in domestic and foreign regulations; ability of manufacture successfully; competition from products manufactured and sold or being developed by other companies; the price of, and demand for, the Company’s products and its ability to raise capital to support its operations. To date, the Company’s operations have not generated sufficient revenues to enable profitability. As of September 30, 2018, the Company had an accumulated deficient of $68.0 million, and incurred recurring losses from operations and incurred recurring negative cash flows from operating activities in prior years. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These unaudited condensed consolidated financial statements do not include any adjustments relating to the realization of the carrying value of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company's continuance as a going concern is dependent on its future profitability and on the on-going support of its shareholders, affiliates and creditors. In order to mitigate the going concern issues, the Company is actively pursuing business partnerships, managing its continuing operations, implementing cost-cutting measures and seeking to sell certain assets. The Company may not be successful in any of these efforts. |
Significant Accounting Policies |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2018 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounting Policies [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Significant Accounting Policies | Summary of Significant Accounting Policies Principles of Consolidation The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated. Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Cash and Cash Equivalents For the purposes of reporting cash flows, the Company considers all cash accounts, which are not subject to withdrawal restrictions or penalties, and highly liquid investments with original maturities of 90 days or less to be cash and cash equivalents. From time to time cash balances exceed federal insurance limits. Restricted Cash As of September 30, 2018 and June 30, 2018 restricted cash included approximately $251,000 and $250,000 respectively, which was pursuant to the requirements in the TD Bank Loan entered into June 2018. (see Note 7) Foreign Currency Translation The Company's functional currency is the US dollar. Transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency are included in the results of operations as incurred. Foreign currency transaction gains or losses included in net loss were immaterial for the three months ended September 30, 2018 and 2017. Accounts Receivable Accounts receivable are recorded at net realizable value. The Company performs ongoing credit evaluations of customers’ financial condition and does not require collateral for accounts receivable arising in the normal course of business. The Company maintains allowances for potential credit losses based on the Company’s historical trends, specific customer issues and current economic trends. Accounts are written off against the allowance when they are determined to be uncollectible based on management’s assessment of individual accounts. The Company recorded an allowance for doubtful accounts of approximately $119,000 as of September 30, 2018 and June 30, 2018. Inventories include freight-in materials, labor and overhead costs, and are stated at the lower of cost (first-in, first-out) or net realizable value. Provision is made for slow-moving , obsolete or unusable inventory. Intangible Assets and Long-Lived Assets Intangible assets deemed to have indefinite lives (including trademark and trade names) and goodwill are not amortized but, instead, are subject to an annual impairment assessment. additionally, if events or conditions were to indicate the carrying value or a reporting unit may not be recoverable, the Company would evaluate goodwill and other intangible assets for impairment at that time. As it relates to the goodwill assessment the Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment testing described in ASU topic No. 350, Intangibles - Goodwill and other. Long-lived assets including intangible assets deemed to have finite lives, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Impairment indicators include, among other conditions, cash flow deficits, historic or anticipated declines in revenue or operating profit or material adverse changes in the business climate that indicate that the carrying amount of an asset may be impaired. When impairment indicators are present, the recoverability of the asset is measured by comparing the carrying value of the asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the projected undiscounted cash flows from the asset are less than the carrying value of the asset the asset is considered to be impaired. The impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. During the year ended June 30, 2018 and the three months ended September 30, 2018, no impairments were recorded. Accrued Warranties The Company provides a limited one year warranty against manufacturer’s defects on its products sold to customers. The Company’s standard warranties require the Company to repair or replace, at the Company’s discretion, defective parts during such warranty period. The Company accrues for its product warranty liabilities based on estimates of costs to be incurred during the warranty period, based on historical repair information for warranty costs. Fair Value of Financial Instruments The carrying amounts for cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued liabilities approximate their fair value because of their short-term maturity. The carrying amount of the accrued post retirement benefits approximates fair value since the Company utilizes approximate current market interest rates to calculate the liability. The Company determined that the carrying amount of the note payable approximates fair value since such debt borrowing bears interest at the approximate current market rate. While the Company believes the carrying value of the assets and liabilities are reasonable, considerable judgment is used to develop estimates of fair value; thus the estimates are not necessarily indicative of the amounts that could be realized in a current market exchange. Revenue Recognition The Company recognizes revenue when its performance obligations with its customers have been satisfied. At contract inception, the Company determines if the contract is within the scope of Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers, and then evaluates the contract using the following five steps: (1) identify the contract with the customer; (2) identify the performance obligations; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. Earnings (Loss) Per Share Earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the year. All outstanding stock options are considered potential common stock. All outstanding convertible preferred stock are considered common stock at the beginning of the period or at the time of issuance, if later, pursuant to the if-converted method. The dilutive effect, if any, of stock options is calculated using the treasury stock method. As of September 30, 2018 and 2017, the average market prices for the three months periods then ended are less than the exercise price of all the outstanding stock options and, therefore, the inclusion of the the stock options would be anti-dilutive. In addition, since the effect of common stock equivalents is anti-dilutive with respect to losses, the convertible preferred stock has also been excluded from the Company’s computation of loss per common for the three months ended September 30, 2018. Therefore, basic and diluted loss per common share for the three-month period ended September 30, 2018 and 2017 are the same.
The following table summarizes convertible preferred stock and securities that, if exercised would have an anti-dilutive effect on earnings per share.
Income Taxes The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. The Company recognizes deferred tax assets to the extent that it believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. As of September 30, 2018 and June 30, 2018, the Company has a fully recorded valuation allowance against its deferred tax assets. The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying unaudited condensed consolidated statements of operations. As of September 30, 2018 and June 30, 2018, no accrued interest or penalties were required to be included on the related tax liability line in the unaudited consolidated consolidated balance sheets. Reclassifications Net revenues in the September 30, 2017 unaudited condensed consolidated statement of operations have been disaggregated to conform to the current period presentation. These reclassifications had no impact on total net revenues or net loss for the three months ended September 30, 2017. New Accounting Pronouncements Recently Issued Accounting Standards The Company considers the applicability and impact of all accounting standards updates ("ASUs"). Management periodically reviews new accounting standards that are issued. New Accounting Pronouncements Recently Adopted In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASC 606”), to clarify the principles of recognizing revenue and create common revenue recognition guidance under US GAAP and International Financial Reporting Standards. This ASU can be adopted either retrospectively to each reporting period presented or as a cumulative effect adjustment as of the date of the adoption. The standard supersedes existing revenue recognition guidance and replaces it with a five-step revenue model with a core principle that an entity recognizes revenue to reflect the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company adopted the new guidance on July 1, 2018. The timing of revenue recognition and treatment of contract costs remains unchanged under Topic 606. As such, the adoption of Topic 606 did not have a material impact on the Company’s unaudited condensed consolidated financial statements. The information presented for the periods prior to July 1, 2018 has not been restated and is reported under the accounting standard in effect for those periods. See Note 10 for further information regarding the Company’s implementation and disclosures in accordance with ASC 606. In August 2016 FASB issued ASU No. 2016-15 Statement of Cash Flows (Topic 230)Classification of Certain Cash Receipts and Cash Payments. The amendments in this Update provide guidance on the eight specific cash flow issues and apply to all entities, including both business entities and not-for-profit entities that are required to present a statement of cash flows under Topic 230. The amendments in this Update are effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption was permitted, including adoption in an interim period. The Company adopted ASU No. 2016-15 on July 1, 2018 using a retrospective transition method. The adoption of this standard did not have an impact on the Company’s consolidated financial statements. In November 2016 the FASB issued ASU 2016-18 Statement of Cash Flows (Topic 230). The amendments in this Update require that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. The amendments in this Update are effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption was permitted, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The Company adopted ASU No. 2016-18 on July 1, 2018. As a result, restricted cash has been included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements. In May 2017 FASB issued the amendments in ASU 2017-09- Compensation-Stock Compensation (“ASC Topic 718”): Scope of Modification Accounting: These amendments provide guidance on determining which changes to the terms and conditions of share-based payment awards require an entity to apply modification accounting under Topic 718. For public companies, these amendments are effective for annual periods beginning after December 15, 2017, including interim periods within those periods. The Company will apply the amendments in this update prospectively to an award modified on or after July 1, 2018 and does not expect that application of this guidance will have a significant impact on the Company’s consolidated financial position or results of operations. New Accounting Pronouncements Not yet Adopted In February 2016 FASB issued ASU No. 2016-02, Leases (Topic 842), which supersedes the existing guidance for lease accounting, Leases (Topic 840). ASU 2016-02 requires lessees to recognize leases on their balance sheets, and leaves lessor accounting largely unchanged. the amendments in this ASU are effective for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years. Early application is permitted for all entities. ASU 2016-02 requires a modified retrospective approach for all leases existing at, or entered into after, the date of initial application, with an option to elect to use certain transition relief. In July 2018, the FASB issued ASU No. 2018-10, "Codification Improvements to Topic 842, Leases." The amendments in ASU 2018-10 clarify, correct or remove inconsistencies in the guidance provided under ASU 2016-02 related to sixteen specific issues identified. Also in July 2018, the FASB issued ASU No. 2018-11 "Leases (Topic 842): Targeted Improvement" which now allows entities the option of recognizing the cumulative effect of applying the new standard as an adjustment to the opening balance of retained earnings in the year of adoption while continuing to present all prior periods under previous lease accounting guidance. The effective date and transition requirements for these two ASUs are the same as the effective date and transition requirements as ASU 2016-02. The Company is currently evaluating the impact of this new standard on its unaudited condensed consolidated financial statements but has not determined the efefcts that the adoption of the pronouncement may have on its unaudited condensed consolidated financial statements and related disclosures. In June 2016 the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which adds a new Topic 326 to the Codification and removes the thresholds that companies apply to measure credit losses on financial instruments measured at amortized cost, such as loans, receivables, and held-to-maturity debt securities. The guidance in ASU 2016-13 is effective for “public business entities,” as defined, that are SEC filers for fiscal years and for interim periods with those fiscal years beginning after December 15, 2019. Early adoption of the guidance is permitted for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years.The adoption of this standard is not expected to have a material impact to the Company’s consolidated financial statements. In January 2017 FASB issued Accounting Standards Update No. 2017-04 Intangibles—Goodwill and Other (Topic 350)Simplifying the Test for Goodwill Impairment.Under the amendments in this update an entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. Additionally, an entity should consider income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss, if applicable. The amendments in this Update are required for public business entities and other entities that have goodwill reported in their financial statements and have not elected the private company alternative for the subsequent measurement of goodwill. A public business entity that is a U.S. Securities and Exchange Commission (SEC) filer should adopt the amendments in this Update for its annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. The adoption of this standard is not expected to have a material impact to the Company’s consolidated financial statements. In June 2018 the FASB issued ASU 2018-07 "Improvements to Nonemployee Share-Based Payment Accounting (Topic 718)" that expands the scope to include share-based payment transactions for acquiring goods and services from non-employees. An entity should apply the requirements to nonemployee awards except for certain exemptions specified in the amendment. The guidance is effective for fiscal years beginning after December 15, 2018, including interim reporting periods within that fiscal year. Early adoption is permitted. The Company does not anticipate the adoption of ASU 2018-07 will have a material impact on the Company's financial condition or results of operations. |
Inventory (Notes) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2018 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventory Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventory Disclosure [Text Block] | Inventories
|
Discontinued operation (Notes) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2018 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] | Discontinued Operations BH Holdings, S.A.S ("BHH") Drew Scientific, Inc. ("Drew"), an inactive subsidiary of the Company which was sold in 2012 has a controlling interest in BHH Holidngs, S.A.S ("BHH). On January 12, 2012 BHH, initiated the filing of an insolvency declaration with the Tribunal de Commerce de Rennes, France ("Commercial Court"). The Commercial Court on January 18, 2012 opened the liquidation proceedings with continuation of BHH's activity for three months and named an administrator to manage BHH. Since Drew no longer had a controlling financial interest in BHH it was deconsolidated in the December 31, 2011 quarterly consolidated financial statements and prior period amounts are presented as discontinued operations. Assets and liabilities of discontinued operations of BHH included in the unaudited consolidated balance sheets are summarized as follows at September 30, 2018 and June 30, 2018 (in thousands):
During fiscal year 2015 the Company was informed by French Counsel that the total amount claimed by the BHH landlord in the liquidation of BHH was approximately $86,000. The Company did not have insight into the French liquidation process due to the Liquidator's reticence to communicate with the Company. As such, the Company had accrued the present value of the maximum amount potentially due under the lease guaranteed by the Company on behalf of BHH. The landlord's claim under liquidation of approximately $86,000 cannot be revisited by the landlord and can only be potentially increased by interest or sundry expenses. Beginning in 2016 any changes to this liability are included in continuing operations. As of September 30, 2018 and June 30, 2018 the liability was approximately $93,000 and $93,000, respectively. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BH Holdings, S.A.S [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disposal Groups, Including Discontinued Operations [Table Text Block] | Assets and liabilities of discontinued operations of BHH included in the unaudited consolidated balance sheets are summarized as follows at September 30, 2018 and June 30, 2018 (in thousands):
|
Related Party Transactions |
3 Months Ended |
---|---|
Sep. 30, 2018 | |
Related Party Transactions [Abstract] | |
Related Party Transactions | . Related Party Transactions and Preferred Stock Richard J. DePiano, Sr., (“Mr. DePiano”), the Company’s Chairman, participated in an accounts receivable factoring program that was implemented by the Company. Under the program, Mr. DePiano advanced the Company $545,000 as of June 30, 2017 and advanced an additional $100,000 during fiscal year 2018 prior to the Debt Exchange Agreement noted below. Interest on the transaction was 1.25% per month. The transactions excluded fees typically charged by the factoring agent and provided much needed liquidity to the Company. Related party interest expense for the three-month periods ended September 30, 2018 and 2017 was $0 and $23,112, respectively. As both of September 30, 2018 and June 30, 2018, accrued interest was $112,389 and was recorded in accrued expenses. On February 14, 2018, the Company entered into a Debt Exchange Agreement (the “Exchange Agreement”) with Mr. DePiano, the Company's Chairman and DP Associates Inc. Profit-Sharing Plan of which Mr. DePiano is the sole owner and sole trustee (the “Holders”). Pursuant to the terms of the Exchange Agreement, effective February 15, 2018, the Holders exchanged a total of $645,000 principal amount of debt related to the accounts receivable factoring program the Company owes the Holders for 2,000,000 shares of Series A Convertible Preferred Stock (the “Preferred Stock”). Each share of Preferred Stock entitles the Holder thereof to 13 votes per share and will vote together with all other classes and series of stock of the Company as a single class on all actions to be taken by the Company’s stockholders. As a result of this voting power, the Holders as of September 30, 2018 beneficially own approximately 77.81% of the voting power on all actions to be taken by the Company’s shareholders. Subject to the terms and conditions of Preferred Stock, the holder of any share or shares of the Preferred Stock has the right, at its option at any time, to convert each such share of Preferred Stock (except that, upon any liquidation of the Company, the right of conversion will terminate at the close of business on the business day fixed for payment of the amounts distributable on the Preferred Stock) into 2.15 shares of Common Stock (the “Conversion Ratio”). The Conversion Ratio is subject standard provisions for adjustment in the event of a subdivision or combination of the Company’s Common Stock and upon any reorganization or reclassification of the capital stock of the Company. If the Holders were to convert their shares of Preferred Stock into Common Stock at the Conversion Ratio the Holders would receive a total of 4,300,000 shares of Common Stock, or approximately 36.70% of the currently outstanding shares of Common Stock assuming such conversion. Each outstanding share of the Preferred Stock accrues dividends calculated cumulatively at the annual rate of $.0258 per share (such amount subject to equitable adjustment in the event of any stock dividend, stock split, combination, reclassification other similar event), payable upon the earlier of (i) a liquidation, dissolution or winding up of the Company or (ii) conversion of the Preferred Stock into Common Stock. Upon either of such events, all such accrued and unpaid dividends, whether or not earned or declared, to and until the date of such event, will become immediately due and payable and will be paid in full. The dividends payable to the holders of the Preferred Stock is payable in cash or, at the election of any such holder, in a number of additional shares of Common Stock equal to the amount of the dividend expressed in dollars divided by the then applicable Conversion Ratio, described above. As of both September 30, 2018 and June 30, 2018 the cumulative dividends payable is $32,373 ($0.0162 per share) and $19,368 ($0.0097 per share), respectively. |
Line of credit (Notes) |
3 Months Ended |
---|---|
Sep. 30, 2018 | |
Line of Credit Facility [Line Items] | |
Debt Disclosure [Text Block] | . Line of Credit On December 29, 2016, the Company entered into a credit agreement providing the Company up to an aggregate of $250,000 in cash, secured by the Company’s inventory. The Company, and its wholly owned subsidiary Sonomed, Inc., entered into an Inventory Advance Agreement as of December 29, 2016 (the "Agreement"), with CDS Business Services, Inc., doing business as Newtek Business Credit ("Newtek"). Newtek made in its discretion loans against the Company’s Eligible Inventory in an aggregate amount outstanding at any time up to the lesser of (i) fifty percent (50%) of the Inventory Value or (ii) the Inventory Advance Limit, as those terms were defined in the Agreement, which was $250,000. The credit agreement renewed annually and could be terminated upon 90 days written notice from the Company or 30 days written notice from Newtek. Interest accrued on the daily balance at the per annum rate of 5.00% above the Prime Rate, but not less than 5.0%. All interest payable by under the financing documents was computed on the basis of a 360 day year for the actual number of days elapsed on the daily balance. The Company was also obligated to pay to Newtek a closing fee equal to 1.00% of the Advance Limit. Upon any renewal of the Agreement, an annual fee was due from Company equal to 1.00% of the Advance Limit. In consideration of monitoring, ledgering and other administrative functions undertaken by Newtek in connection with the Company’s inventory, and the merchant processor, Company was obligated pay Newtek a monthly collateral monitoring fee calculated by multiplying (i) seventy basis points (0.70%) (approximately an annual rate of 8.5%) (except during the existence of an Event of Default at which time it shall be 1%) by (ii) the amount of the average daily balances during the calendar month preceding the month for which the calculation is made. On June 29, 2018 the Company entered a business loan agreement with TD bank receiving a line of credit evidenced by a promissory note of $250,000. The interest is subject to change based on changes in an independent index which the Wall Street Journal Prime. The index rate at the date of the agreement is 5.000% per annum. Interest on the unpaid principal balance of the note is calculated using a rate of 0.740 percentage points over the index, adjusted if necessary for any minimum and maximum rate limitations, resulting in an initial rate of 5.740% per annum based on a year of 360 days. The Company was required to put $250,000 in the TD bank savings account as collateral. Mr. Richard J. DePiano chairman of the Company executed a guarantee of the loan in favor of TD Bank. Upon signing the agreement the Company also authorizes TD bank to payoff the line of credit with Netwtek. The total payment was $201,575 which includes $165,000 of outstanding line of credit, $2,579 accrued interest, administrative/legal fee of $1,000, prime plus fee through July 12, 2018 of $1,895 and underminimum fees of $28,797. The underminimum fees of $28,797 was included in accrued expense as of June 30, 2018. As of September 30, 2018 and June 30, 2018 , the line of credit balance was $201,575 with TD bank and $165,000 from CDS Bushiness Services Inc. The line of credit interest expense was $6,581 and $10,336 for the three-month periods ended September 30, 2018 and September 30, 2017 respectively. The line of credit from CDS Business services, Inc. was paid off on July 3, 2018. |
Commitments and Contingencies |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2018 | |||||||||||||||||||||||||||||||||||||||||
Commitments and Contingencies Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||
Commitments and Contingencies | Commitments and Contingencies Commitments The Company leases its manufacturing, research and corporate office facilities and certain equipment under non-cancelable operating lease arrangements. The future annual amounts to be paid under these arrangements as of September 30, 2018 are as follows:
Legal Proceedings The Company, from time to time is involved in various legal proceedings and disputes that arise in the normal course of business. These matters have included intellectual property disputes, contract disputes, employment disputes and other matters. The Company does not believe that the resolution of any of these matters has had or is likely to have a material adverse impact on the Company’s business, financial condition or results of operations. |
Concentration of credit risk (Notes) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2018 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Concentration Risk [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Concentration Risk Disclosure [Text Block] | Concentration of Credit Risk Credit Risk Financial Instruments, which potentially subject the Company to concentration of credit risk, consist principally of cash and cash equivalents, and trade receivables. Concentration of credit risk with respect to trade receivables is generally diversified due to the large number of entities comprising the Company's customer base and their dispersion across geographic areas principally within the United States and international. The Company routinely address the financial strength of its customer and, as a consequence, believes that its receivable credit risk exposure is limited. The Company does not require customers to post collateral. Major Customer No customer accounted for more than 10% of net sales during the three months ended September 30, 2018 and 2017. As of September 30, 2018 the Company had one customer that represents approximately 12% of the total accounts receivable balance. As of June 30, 2018 the Company had one customer that represents approximately 11% of the total accounts receivable balance. Major supplier Our two largest suppliers accounted for of total purchases for more than 36% for the three-month periods ended September 30, 2018 and one largest supplier accounted for 38% of total purchase for the three-month periods ended September 30, 2017. Foreign sales Domestic and international sales from continuing operations are as follows:
|
Revenue from contracts with customers (Notes) |
3 Months Ended | ||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2018 | |||||||||||||||||||||||||||||
Revenue from Contract with Customer [Abstract] | |||||||||||||||||||||||||||||
Revenue from Contract with Customer [Text Block] | 10. Revenue from Contracts with Customers The Company adopted the new guidance on July 1, 2018, using the modified retrospective transition method and applying this approach to those contracts that were not completed as of that date. Under ASC 606, the Company recognizes revenue when its performance obligations with its customers have been satisfied. The Company generates product revenue from the sale of medical device products and the sale and installation of the Company's AXIS image management system software. Revenue for service plans relate to the customer care plans for the Company’s equipment and AXIS image management system software. Revenue Recognition Revenue is recognized upon transfer of control of the promised goods or services to the customer for an amount that reflects the consideration that the Company expects to be entitled in exchange for those goods or services. The Company’s performance obligations are for product sales, installation of AXIS image management system software and customer care plans. The performance obligations are determined at contract inception based upon promises within the contract that are distinct. The product sales and installation of AXIS image management system software performance obligations are satisfied at a point in time, which is upon shipment for product sales and upon successful installation for the AXIS image management system. The performance obligation for customer care plans is satisfied over time as the customer receives and consumes the Company’s services. The Company invoices its customers upon shipment for product sales. For the installation of AXIS image management system software and customer care plans, the Company invoices its customers upon successful installation. Invoice payments are generally due within 30 days of invoice date. The transaction price is determined based on fixed consideration in the Company’s customer contracts and is recorded net of variable consideration. In determining the transaction price, a significant financing component does not exist since the timing from when the Company invoices its customers to when payment is received as it is less than one year. Revenue for product sales and installation of AXIS image management system software is recognized when delivered or installed. The customer care plan revenues are recognized proportionately over the service period, which is a 12-month period. The Company has elected the following practical expedients in applying ASC 606:
Deferred Revenues The Company records deferred revenues when cash payments are received or due in advance of its performance. The Company’s deferred revenues relate to payments received for the customer care plan for a 12-month period. The consideration received is recognized monthly over the service period. As of June 30, 2018, the Company’s deferred revenue balance was approximately $481,000, of which $235,000 was recognized as revenue during the three-month period ended September 30, 2018. The Company recorded $252,000 in deferred revenue during the three-month period ended September 30, 2018 that relates to unsatisfied performance obligations. |
Significant Accounting Policies (Policies) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2018 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounting Policies [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restrictions on Cash and Cash Equivalents [Table Text Block] | As of September 30, 2018 and June 30, 2018 restricted cash included approximately $251,000 and $250,000 respectively, which was pursuant to the requirements in the TD Bank Loan entered into June 2018. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Foreign Currency Transactions and Translations Policy [Policy Text Block] | The Company's functional currency is the US dollar. Transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency are included in the results of operations as incurred. Foreign currency transaction gains or losses included in net loss were immaterial for the three months ended September 30, 2018 and 2017. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Principles of Consolidation | The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Use of Estimates | The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cash and Cash Equivalents | For the purposes of reporting cash flows, the Company considers all cash accounts, which are not subject to withdrawal restrictions or penalties, and highly liquid investments with original maturities of 90 days or less to be cash and cash equivalents. From time to time cash balances exceed federal insurance limits. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value of Financial Instruments | The carrying amounts for cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued liabilities approximate their fair value because of their short-term maturity. The carrying amount of the accrued post retirement benefits approximates fair value since the Company utilizes approximate current market interest rates to calculate the liability. The Company determined that the carrying amount of the note payable approximates fair value since such debt borrowing bears interest at the approximate current market rate. While the Company believes the carrying value of the assets and liabilities are reasonable, considerable judgment is used to develop estimates of fair value; thus the estimates are not necessarily indicative of the amounts that could be realized in a current market exchange. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Revenue Recognition | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventory | Inventories include freight-in materials, labor and overhead costs, and are stated at the lower of cost (first-in, first-out) or net realizable value. Provision is made for slow-moving , obsolete or unusable inventory. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounts Receivable | Accounts receivable are recorded at net realizable value. The Company performs ongoing credit evaluations of customers’ financial condition and does not require collateral for accounts receivable arising in the normal course of business. The Company maintains allowances for potential credit losses based on the Company’s historical trends, specific customer issues and current economic trends. Accounts are written off against the allowance when they are determined to be uncollectible based on management’s assessment of individual accounts. The Company recorded an allowance for doubtful accounts of approximately $119,000 as of September 30, 2018 and June 30, 2018. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Intangible Assets | Intangible assets deemed to have indefinite lives (including trademark and trade names) and goodwill are not amortized but, instead, are subject to an annual impairment assessment. additionally, if events or conditions were to indicate the carrying value or a reporting unit may not be recoverable, the Company would evaluate goodwill and other intangible assets for impairment at that time. As it relates to the goodwill assessment the Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment testing described in ASU topic No. 350, Intangibles - Goodwill and other. Long-lived assets including intangible assets deemed to have finite lives, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Impairment indicators include, among other conditions, cash flow deficits, historic or anticipated declines in revenue or operating profit or material adverse changes in the business climate that indicate that the carrying amount of an asset may be impaired. When impairment indicators are present, the recoverability of the asset is measured by comparing the carrying value of the asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the projected undiscounted cash flows from the asset are less than the carrying value of the asset the asset is considered to be impaired. The impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. During the year ended June 30, 2018 and the three months ended September 30, 2018, no impairments were recorded. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued Warranties | The Company provides a limited one year warranty against manufacturer’s defects on its products sold to customers. The Company’s standard warranties require the Company to repair or replace, at the Company’s discretion, defective parts during such warranty period. The Company accrues for its product warranty liabilities based on estimates of costs to be incurred during the warranty period, based on historical repair information for warranty costs. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net Income (loss) Per Share | Earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the year. All outstanding stock options are considered potential common stock. All outstanding convertible preferred stock are considered common stock at the beginning of the period or at the time of issuance, if later, pursuant to the if-converted method. The dilutive effect, if any, of stock options is calculated using the treasury stock method. As of September 30, 2018 and 2017, the average market prices for the three months periods then ended are less than the exercise price of all the outstanding stock options and, therefore, the inclusion of the the stock options would be anti-dilutive. In addition, since the effect of common stock equivalents is anti-dilutive with respect to losses, the convertible preferred stock has also been excluded from the Company’s computation of loss per common for the three months ended September 30, 2018. Therefore, basic and diluted loss per common share for the three-month period ended September 30, 2018 and 2017 are the same.
The following table summarizes convertible preferred stock and securities that, if exercised would have an anti-dilutive effect on earnings per share.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Income Taxes | The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. The Company recognizes deferred tax assets to the extent that it believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. As of September 30, 2018 and June 30, 2018, the Company has a fully recorded valuation allowance against its deferred tax assets. The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying unaudited condensed consolidated statements of operations. As of September 30, 2018 and June 30, 2018, no accrued interest or penalties were required to be included on the related tax liability line in the unaudited consolidated consolidated balance sheets. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reclassifications [Text Block] | in the September 30, 2017 unaudited condensed consolidated statement of operations have been disaggregated to conform to the current period presentation. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
New Accounting Pronouncements | Recently Issued Accounting Standards The Company considers the applicability and impact of all accounting standards updates ("ASUs"). Management periodically reviews new accounting standards that are issued. New Accounting Pronouncements Recently Adopted In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASC 606”), to clarify the principles of recognizing revenue and create common revenue recognition guidance under US GAAP and International Financial Reporting Standards. This ASU can be adopted either retrospectively to each reporting period presented or as a cumulative effect adjustment as of the date of the adoption. The standard supersedes existing revenue recognition guidance and replaces it with a five-step revenue model with a core principle that an entity recognizes revenue to reflect the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company adopted the new guidance on July 1, 2018. The timing of revenue recognition and treatment of contract costs remains unchanged under Topic 606. As such, the adoption of Topic 606 did not have a material impact on the Company’s unaudited condensed consolidated financial statements. The information presented for the periods prior to July 1, 2018 has not been restated and is reported under the accounting standard in effect for those periods. See Note 10 for further information regarding the Company’s implementation and disclosures in accordance with ASC 606. In August 2016 FASB issued ASU No. 2016-15 Statement of Cash Flows (Topic 230)Classification of Certain Cash Receipts and Cash Payments. The amendments in this Update provide guidance on the eight specific cash flow issues and apply to all entities, including both business entities and not-for-profit entities that are required to present a statement of cash flows under Topic 230. The amendments in this Update are effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption was permitted, including adoption in an interim period. The Company adopted ASU No. 2016-15 on July 1, 2018 using a retrospective transition method. The adoption of this standard did not have an impact on the Company’s consolidated financial statements. In November 2016 the FASB issued ASU 2016-18 Statement of Cash Flows (Topic 230). The amendments in this Update require that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. The amendments in this Update are effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption was permitted, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The Company adopted ASU No. 2016-18 on July 1, 2018. As a result, restricted cash has been included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements. In May 2017 FASB issued the amendments in ASU 2017-09- Compensation-Stock Compensation (“ASC Topic 718”): Scope of Modification Accounting: These amendments provide guidance on determining which changes to the terms and conditions of share-based payment awards require an entity to apply modification accounting under Topic 718. For public companies, these amendments are effective for annual periods beginning after December 15, 2017, including interim periods within those periods. The Company will apply the amendments in this update prospectively to an award modified on or after July 1, 2018 and does not expect that application of this guidance will have a significant impact on the Company’s consolidated financial position or results of operations. New Accounting Pronouncements Not yet Adopted In February 2016 FASB issued ASU No. 2016-02, Leases (Topic 842), which supersedes the existing guidance for lease accounting, Leases (Topic 840). ASU 2016-02 requires lessees to recognize leases on their balance sheets, and leaves lessor accounting largely unchanged. the amendments in this ASU are effective for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years. Early application is permitted for all entities. ASU 2016-02 requires a modified retrospective approach for all leases existing at, or entered into after, the date of initial application, with an option to elect to use certain transition relief. In July 2018, the FASB issued ASU No. 2018-10, "Codification Improvements to Topic 842, Leases." The amendments in ASU 2018-10 clarify, correct or remove inconsistencies in the guidance provided under ASU 2016-02 related to sixteen specific issues identified. Also in July 2018, the FASB issued ASU No. 2018-11 "Leases (Topic 842): Targeted Improvement" which now allows entities the option of recognizing the cumulative effect of applying the new standard as an adjustment to the opening balance of retained earnings in the year of adoption while continuing to present all prior periods under previous lease accounting guidance. The effective date and transition requirements for these two ASUs are the same as the effective date and transition requirements as ASU 2016-02. The Company is currently evaluating the impact of this new standard on its unaudited condensed consolidated financial statements but has not determined the efefcts that the adoption of the pronouncement may have on its unaudited condensed consolidated financial statements and related disclosures. In June 2016 the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which adds a new Topic 326 to the Codification and removes the thresholds that companies apply to measure credit losses on financial instruments measured at amortized cost, such as loans, receivables, and held-to-maturity debt securities. The guidance in ASU 2016-13 is effective for “public business entities,” as defined, that are SEC filers for fiscal years and for interim periods with those fiscal years beginning after December 15, 2019. Early adoption of the guidance is permitted for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years.The adoption of this standard is not expected to have a material impact to the Company’s consolidated financial statements. In January 2017 FASB issued Accounting Standards Update No. 2017-04 Intangibles—Goodwill and Other (Topic 350)Simplifying the Test for Goodwill Impairment.Under the amendments in this update an entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. Additionally, an entity should consider income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss, if applicable. The amendments in this Update are required for public business entities and other entities that have goodwill reported in their financial statements and have not elected the private company alternative for the subsequent measurement of goodwill. A public business entity that is a U.S. Securities and Exchange Commission (SEC) filer should adopt the amendments in this Update for its annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. The adoption of this standard is not expected to have a material impact to the Company’s consolidated financial statements. In June 2018 the FASB issued ASU 2018-07 "Improvements to Nonemployee Share-Based Payment Accounting (Topic 718)" that expands the scope to include share-based payment transactions for acquiring goods and services from non-employees. An entity should apply the requirements to nonemployee awards except for certain exemptions specified in the amendment. The guidance is effective for fiscal years beginning after December 15, 2018, including interim reporting periods within that fiscal year. Early adoption is permitted. The Company does not anticipate the adoption of ASU 2018-07 will have a material impact on the Company's financial condition or results of operations. |
Significant Accounting Policies (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2018 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] | The following table summarizes convertible preferred stock and securities that, if exercised would have an anti-dilutive effect on earnings per share.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] |
|
Inventory (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2018 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventory Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Inventory, Current [Table Text Block] |
|
Commitments and Contingencies (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2018 | |||||||||||||||||||||||||||||||||||||||||
Commitments and Contingencies Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||
Schedule of Future Minimum Rental Payments for Operating Leases | The future annual amounts to be paid under these arrangements as of September 30, 2018 are as follows:
|
Concentration of credit risk (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2018 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Concentration Risk [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedules of Concentration of Risk, by Risk Factor [Table Text Block] | Concentration of Credit Risk Credit Risk Financial Instruments, which potentially subject the Company to concentration of credit risk, consist principally of cash and cash equivalents, and trade receivables. Concentration of credit risk with respect to trade receivables is generally diversified due to the large number of entities comprising the Company's customer base and their dispersion across geographic areas principally within the United States and international. The Company routinely address the financial strength of its customer and, as a consequence, believes that its receivable credit risk exposure is limited. The Company does not require customers to post collateral. Major Customer No customer accounted for more than 10% of net sales during the three months ended September 30, 2018 and 2017. As of September 30, 2018 the Company had one customer that represents approximately 12% of the total accounts receivable balance. As of June 30, 2018 the Company had one customer that represents approximately 11% of the total accounts receivable balance. Major supplier Our two largest suppliers accounted for of total purchases for more than 36% for the three-month periods ended September 30, 2018 and one largest supplier accounted for 38% of total purchase for the three-month periods ended September 30, 2017. Foreign sales Domestic and international sales from continuing operations are as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] | Foreign sales Domestic and international sales from continuing operations are as follows:
|
Significant Accounting Policies (Cash and Cash Equivalents) (Details) |
3 Months Ended |
---|---|
Sep. 30, 2018 | |
Accounting Policies [Abstract] | |
Maximum maturity of highly liquid investments, period | 90 days |
Significant Accounting Policies (Net Income (loss) Per Share) (Details) - shares |
3 Months Ended | |
---|---|---|
Sep. 30, 2018 |
Sep. 30, 2017 |
|
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Basic Weighted average shares outstanding | 7,415,329 | 7,551,430 |
Weighted average shares - diluted | 7,415,329 | 7,551,430 |
Inventory (Details) - USD ($) |
Sep. 30, 2018 |
Jun. 30, 2018 |
---|---|---|
Inventory Disclosure [Abstract] | ||
Raw Materials | $ 616,000 | $ 653,000 |
Work in process | 240,000 | 192,000 |
Finished goods | 912,000 | 978,000 |
Inventory, net | $ 1,765,182 | $ 1,823,414 |
Discontinued operation (Details) - USD ($) $ in Thousands |
Jan. 18, 2012 |
Sep. 30, 2018 |
Jun. 30, 2018 |
Jun. 30, 2015 |
---|---|---|---|---|
BH Holdings, S.A.S [Member] | ||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||||
Disposal Group, Including Discontinued Operation, Assets | $ 0 | $ 0 | ||
Disposal Group, Including Discontinued Operation, Other Liabilities, Current | 93 | 93 | $ 86 | |
Disposal Group, Including Discontinued Operation, Liabilities | 93 | 93 | ||
Assets (Liabilities) of Disposal Group, Including Discontinued Operation, Net | $ (93) | $ (93) | ||
BH Holdings, S.A.S [Member] | ||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||||
Bankruptcy Proceedings, Operating Period During Liquidation | 3 months |
Related Party Transactions (Details) - USD ($) |
3 Months Ended | 12 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2018 |
Sep. 30, 2017 |
Jun. 30, 2018 |
Mar. 31, 2018 |
|
Related Party Transaction [Line Items] | ||||
Related Party Transaction, Amounts of Transaction | $ 100,000 | $ 545,000 | ||
Related Party Transaction, Rate | 1.30% | |||
Interest Expense, Related Party | $ 0 | $ 23,112 | ||
accrued interest related party | $ 112,389 | |||
Related Party Transaction, Due from (to) Related Party | $ 645,000 | |||
Preferred Stock, Shares Issued | 2,000,000 | 2,000,000 | ||
Convertible Preferred Stock, Shares Issued upon Conversion | 2.15 | |||
Common Stock, Conversion Basis | 4300000 | |||
Equity Method Investment, Ownership Percentage | 36.70% | |||
Dividends | $ 13,005 | |||
Dividends Payable, Date to be Paid | $ 32,373 | $ 19,368 | ||
Dividends Payable, Amount Per Share | $ (0.01) | $ (0.03) |
Commitments and Contingencies (Details) |
Sep. 30, 2018
USD ($)
|
---|---|
Commitments and Contingencies Disclosure [Abstract] | |
2019 | $ 273,275 |
2020 | 268,469 |
2021 | 182,972 |
2022 | 178,535 |
2023 | 183,892 |
thereafter | 286,239 |
Leases, Operating [Abstract] | |
Operating Leases, Future Minimum Payments Due | $ 1,373,382 |
Concentration of credit risk (Details) - USD ($) |
3 Months Ended | 12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2018 |
Sep. 30, 2017 |
Jun. 30, 2018 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Concentration Risk [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedules of Concentration of Risk, by Risk Factor [Table Text Block] | Concentration of Credit Risk Credit Risk Financial Instruments, which potentially subject the Company to concentration of credit risk, consist principally of cash and cash equivalents, and trade receivables. Concentration of credit risk with respect to trade receivables is generally diversified due to the large number of entities comprising the Company's customer base and their dispersion across geographic areas principally within the United States and international. The Company routinely address the financial strength of its customer and, as a consequence, believes that its receivable credit risk exposure is limited. The Company does not require customers to post collateral. Major Customer No customer accounted for more than 10% of net sales during the three months ended September 30, 2018 and 2017. As of September 30, 2018 the Company had one customer that represents approximately 12% of the total accounts receivable balance. As of June 30, 2018 the Company had one customer that represents approximately 11% of the total accounts receivable balance. Major supplier Our two largest suppliers accounted for of total purchases for more than 36% for the three-month periods ended September 30, 2018 and one largest supplier accounted for 38% of total purchase for the three-month periods ended September 30, 2017. Foreign sales Domestic and international sales from continuing operations are as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Concentration Risk, Customer | 0.1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Concentration Risk, Credit Risk, Financial Instruments | 0.12 | 0.11 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Concentration Risk, Supplier | 0.36 | 0.38 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Revenue, Net | $ 2,258,383 | $ 2,629,624 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sales Revenue, Net [Member] | Geographic Concentration Risk [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Concentration Risk [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Revenue, Net | $ 2,258,000 | $ 2,630,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Concentration Risk, Percentage | 100.00% | 100.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Domestic [Member] | Sales Revenue, Net [Member] | Geographic Concentration Risk [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Concentration Risk [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Revenue, Net | $ 1,469,000 | $ 1,747,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Concentration Risk, Percentage | 65.06% | 66.43% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
International [Member] | Sales Revenue, Net [Member] | Geographic Concentration Risk [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Concentration Risk [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Revenue, Net | $ 789,000 | $ 883,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Concentration Risk, Percentage | 34.94% | 33.57% |
Revenue from contracts with customers (Details) - USD ($) |
3 Months Ended | |
---|---|---|
Sep. 30, 2018 |
Jun. 30, 2018 |
|
Movement in Deferred Revenue [Roll Forward] | ||
Deferred Revenue | $ 498,000 | $ 481,000 |
Deferred Revenue, Additions | 252,000 | |
Deferred Revenue, Revenue Recognized | $ 235,000 |
Label | Element | Value |
---|---|---|
Restricted Cash | us-gaap_RestrictedCash | $ 0 |
Restricted Cash | us-gaap_RestrictedCash | 250,000 |
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | 544,118 |
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | $ 1,124,002 |
S9PG-G@V3_(LZSH>-#JZU%7R [-;67/G1(4\
M!?59=:54@(SIK62X0MY>0X/ 5:AJ(NNL.\.[AJ!-?SVAX8[,_P%02P,$%
M @ .H5N3:&]Z(N& P Q0X !@ !X;"]W;W)K _*7)AV^&XE-253#(
MR\[CI+J-8+G1'/](_ZO)[I(5O-\!W,<4;D VQW7A-W$D W? .9\C4:FB,IVG
M,-CU*HVC/.V\]R:_@Z\!,7N??JAO 3?GP=K;[WPJ:CCL[>]N_\]6V?O5E)>4B>>GV
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MJA6\7ZANMCL,=U5&P.NI9WR9X3;(H WJT 9'339E)77X$$5(LZ5@LKAVWFZ;W?QP;H=HD[J!*1GD#0B'YKRJP"^#$P80[:
M0Y4LT_H!:/X2=*-DSE Q1T*,0 :.T:9YGZ[0QZ$_1J!C W;(@;GCXXTU>0+<
M#F$$PNH"Y3;ZRRL(2T
I2!]JD+K^"XJG%E5$6GG#Y=(1R(D((E1*/9QP9D#=)&O4&X!
ME%O)9RC:TO[]1P="=!)$:4'(8@/X(&B
>9Y0([EHD2-Y\
MNEJ,ZF*DF=F.R#AAAE'3GTA!5ACR@